Heat Biologics Inc (NASDAQ:HTBX) a Buy: Cantor Fitzgerald

In a research note issued to investors, Mara Goldstein at Cantor Fitzgerald Reiterated their Buy rating on Heat Biologics Inc (NASDAQ:HTBX). The analyst placed a $18.00 price target on the stock which indicates a 209.81% upside to the last closing price. In the year following Goldstein’s ratings, the stocks covered yield an average return of 14.9% according to TipRanks.com. In the past year 42 out of 68 recommendations or 62% were successful.

Wall Street analysts have placed a target price of $18 for Heat Biologics, Inc. (NASDAQ:HTBX). This number is based on the mean consensus estimate from the 1 research firms that recently issued reports on the stock.

The average broker recommendation is arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. On a scale of 1 to 5 where 1 is a Strong Buy and 5 is a Strong Sell, has the stock ranked 1 based on 1 broker recommendations. Of the 1 analysts who have issued estimates, the most bullish sees the stock reaching $18 within the next 12 months while the most conservative sees the stock at $18 within the year.

According to analysts, Heat Biologics, Inc. (NASDAQ:HTBX) is expected to report earnings per share for the current fiscal quarter of $-0.46. This is the consensus mean estimate based on the individual covering sell-side analysts’ reported numbers. The company last reported earnings for the period ending on 2015-03-31 of $-0.57. The reported number was -0.08 away from the consensus estimate, or a surprise factor of -16.33 .

In looking at the long term growth prospects of the company, sell-side analysts have a consensus mean earnings per share estimate for the current year of $N/A. The high end estimate for this time frame is $N/A with the low being $N/A.

Heat Biologics, Inc. (Heat Biologics) is a development-stage biopharmaceutical company engaged in the development of allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers and infectious diseases. Its ImmunePan Antigen Cytotoxic Therapy (ImPACT) is being designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to pump out a range of cancer-associated antigens together with a immune adjuvant called gp96 to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Its primary product candidates are HS-110 and HS-410. It is also developing ImPACT therapeutic vaccines for breast cancer and ovarian cancer.